Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 137

2.

New design of nucleotide excision repair (NER) inhibitors for combination cancer therapy.

Gentile F, Tuszynski JA, Barakat KH.

J Mol Graph Model. 2016 Apr;65:71-82. doi: 10.1016/j.jmgm.2016.02.010. Epub 2016 Feb 26.

PMID:
26939044
3.

Inhibition of the ERCC1-XPF structure-specific endonuclease to overcome cancer chemoresistance.

McNeil EM, Astell KR, Ritchie AM, Shave S, Houston DR, Bakrania P, Jones HM, Khurana P, Wallace C, Chapman T, Wear MA, Walkinshaw MD, Saxty B, Melton DW.

DNA Repair (Amst). 2015 Jul;31:19-28. doi: 10.1016/j.dnarep.2015.04.002. Epub 2015 Apr 22.

PMID:
25956741
4.

Small molecule inhibitors of ERCC1-XPF protein-protein interaction synergize alkylating agents in cancer cells.

Jordheim LP, Barakat KH, Heinrich-Balard L, Matera EL, Cros-Perrial E, Bouledrak K, El Sabeh R, Perez-Pineiro R, Wishart DS, Cohen R, Tuszynski J, Dumontet C.

Mol Pharmacol. 2013 Jul;84(1):12-24. doi: 10.1124/mol.112.082347. Epub 2013 Apr 11.

PMID:
23580445
5.

Identification of small molecule inhibitors of ERCC1-XPF that inhibit DNA repair and potentiate cisplatin efficacy in cancer cells.

Arora S, Heyza J, Zhang H, Kalman-Maltese V, Tillison K, Floyd AM, Chalfin EM, Bepler G, Patrick SM.

Oncotarget. 2016 Nov 15;7(46):75104-75117. doi: 10.18632/oncotarget.12072.

6.

DNA repair endonuclease ERCC1-XPF as a novel therapeutic target to overcome chemoresistance in cancer therapy.

McNeil EM, Melton DW.

Nucleic Acids Res. 2012 Nov 1;40(20):9990-10004. doi: 10.1093/nar/gks818. Epub 2012 Aug 31. Review.

7.

Multiple DNA binding domains mediate the function of the ERCC1-XPF protein in nucleotide excision repair.

Su Y, Orelli B, Madireddy A, Niedernhofer LJ, Schärer OD.

J Biol Chem. 2012 Jun 22;287(26):21846-55. doi: 10.1074/jbc.M111.337899. Epub 2012 Apr 30.

8.

Crystal structure and DNA binding functions of ERCC1, a subunit of the DNA structure-specific endonuclease XPF-ERCC1.

Tsodikov OV, Enzlin JH, Schärer OD, Ellenberger T.

Proc Natl Acad Sci U S A. 2005 Aug 9;102(32):11236-41. Epub 2005 Aug 2.

9.

Catechols and 3-hydroxypyridones as inhibitors of the DNA repair complex ERCC1-XPF.

Chapman TM, Gillen KJ, Wallace C, Lee MT, Bakrania P, Khurana P, Coombs PJ, Stennett L, Fox S, Bureau EA, Brownlees J, Melton DW, Saxty B.

Bioorg Med Chem Lett. 2015 Oct 1;25(19):4097-103. doi: 10.1016/j.bmcl.2015.08.031. Epub 2015 Aug 17.

PMID:
26318993
10.

Function and Interactions of ERCC1-XPF in DNA Damage Response.

Faridounnia M, Folkers GE, Boelens R.

Molecules. 2018 Dec 5;23(12). pii: E3205. doi: 10.3390/molecules23123205. Review.

11.

Physical and functional interaction between the XPF/ERCC1 endonuclease and hRad52.

Motycka TA, Bessho T, Post SM, Sung P, Tomkinson AE.

J Biol Chem. 2004 Apr 2;279(14):13634-9. Epub 2004 Jan 20.

12.

Domain mapping of the DNA binding, endonuclease, and ERCC1 binding properties of the human DNA repair protein XPF.

McCutchen-Maloney SL, Giannecchini CA, Hwang MH, Thelen MP.

Biochemistry. 1999 Jul 20;38(29):9417-25.

PMID:
10413517
13.

Targeting the DNA Repair Endonuclease ERCC1-XPF with Green Tea Polyphenol Epigallocatechin-3-Gallate (EGCG) and Its Prodrug to Enhance Cisplatin Efficacy in Human Cancer Cells.

Heyza JR, Arora S, Zhang H, Conner KL, Lei W, Floyd AM, Deshmukh RR, Sarver J, Trabbic CJ, Erhardt P, Chan TH, Dou QP, Patrick SM.

Nutrients. 2018 Nov 3;10(11). pii: E1644. doi: 10.3390/nu10111644.

14.

Mislocalization of XPF-ERCC1 nuclease contributes to reduced DNA repair in XP-F patients.

Ahmad A, Enzlin JH, Bhagwat NR, Wijgers N, Raams A, Appledoorn E, Theil AF, J Hoeijmakers JH, Vermeulen W, J Jaspers NG, Schärer OD, Niedernhofer LJ.

PLoS Genet. 2010 Mar 5;6(3):e1000871. doi: 10.1371/journal.pgen.1000871.

15.

The structure of the human ERCC1/XPF interaction domains reveals a complementary role for the two proteins in nucleotide excision repair.

Tripsianes K, Folkers G, Ab E, Das D, Odijk H, Jaspers NG, Hoeijmakers JH, Kaptein R, Boelens R.

Structure. 2005 Dec;13(12):1849-58.

16.

Single-stranded DNA Binding by the Helix-Hairpin-Helix Domain of XPF Protein Contributes to the Substrate Specificity of the ERCC1-XPF Protein Complex.

Das D, Faridounnia M, Kovacic L, Kaptein R, Boelens R, Folkers GE.

J Biol Chem. 2017 Feb 17;292(7):2842-2853. doi: 10.1074/jbc.M116.747857. Epub 2016 Dec 27.

17.

Activity of individual ERCC1 and XPF subunits in DNA nucleotide excision repair.

Gaillard PH, Wood RD.

Nucleic Acids Res. 2001 Feb 15;29(4):872-9.

18.

The XPA-binding domain of ERCC1 is required for nucleotide excision repair but not other DNA repair pathways.

Orelli B, McClendon TB, Tsodikov OV, Ellenberger T, Niedernhofer LJ, Schärer OD.

J Biol Chem. 2010 Feb 5;285(6):3705-12. doi: 10.1074/jbc.M109.067538. Epub 2009 Nov 23.

19.

Downregulation of XPF-ERCC1 enhances cisplatin efficacy in cancer cells.

Arora S, Kothandapani A, Tillison K, Kalman-Maltese V, Patrick SM.

DNA Repair (Amst). 2010 Jul 1;9(7):745-53. doi: 10.1016/j.dnarep.2010.03.010. Epub 2010 Apr 24.

20.

Biophysical characterization of the interaction domains and mapping of the contact residues in the XPF-ERCC1 complex.

Choi YJ, Ryu KS, Ko YM, Chae YK, Pelton JG, Wemmer DE, Choi BS.

J Biol Chem. 2005 Aug 5;280(31):28644-52. Epub 2005 Jun 1.

Supplemental Content

Support Center